Study of Cidecin™ (Daptomycin) to Rocephin® (Ceftriaxone) in the Treatment of Moderate to Severe Community-Acquired Acute Bacterial Pneumonia Due to S. Pneumoniae
Clinical trial NCT00540072 · COMPLETED
Trial details
- NCT number
- NCT00540072
- Sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2001-07-30
- Primary completion
- 2002-02-27
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.